Filing Flows › Fate Therapeutics (FATE) › Q1 2026 › vs Q4 2025
Fate Therapeutics (FATE) Q1 2026 vs Q4 2025 (quarter over quarter)
Fate Therapeutics's revenue fell $70K (-5%) from $1.4M in Q4 2025 to $1.3M in Q1 2026.
Fate Therapeutics, Q1 2026: revenue $1.3M (-20% year over year), net loss $31.2M, operating cash flow −$30.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3M | $1.4M | −$70K | -5% |
| Other income, net | $1.8M | $2.3M | −$560K | -24% |
| Net loss | $31.2M | $32.4M | −$1.2M | -4% |
| Costs & expenses | $34.3M | $36.1M | −$1.8M | -5% |
| Operating costs | $34.3M | $36.1M | −$1.8M | -5% |
| Research & development | $24.7M | $25.4M | −$722K | -3% |
| General & admin | $9.6M | $10.7M | −$1.1M | -10% |
| Operating cash sources | $37.7M | $31.9M | $5.8M | +18% |
| Depreciation & amortization | $2.9M | $3.1M | −$145K | -5% |
| Share-based compensation | $3.9M | $5.5M | −$1.6M | -29% |
| Cash used in operations | $30.8M | $23.3M | $7.5M | +32% |
| Net loss absorbed | $31.2M | $32.4M | −$1.2M | -4% |
| Working capital & other | $6.5M | −$469K | $6.9M | — |
Questions
How much did Fate Therapeutics's revenue grow quarter over quarter in Q1 2026?
Fate Therapeutics's revenue fell $70K (-5%) from $1.4M in Q4 2025 to $1.3M in Q1 2026.